Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC

被引：58

作者：

Medema, Rene H. ^{[1
,2
]}

Lin, Chia-Chi ^{[3
]}

Yang, James Chih-Hsin ^{[3
,4
,5
]}

机构：

[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands

[2] Univ Med Ctr Utrecht, Canc Genom Ctr, Utrecht, Netherlands

[3] Natl Taiwan Univ, Dept Oncol, Taipei 10764, Taiwan

[4] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan

[5] Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan

来源：

CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 20期

关键词：

CELL LUNG-CANCER; PHASE-III TRIAL; SMALL INTERFERING RNA; CHEMOTHERAPY REGIMENS; TUMOR-GROWTH; BI; 2536; PLK1; MUTATIONS; DOCETAXEL; CARBOPLATIN;

D O I：

10.1158/1078-0432.CCR-11-0541

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cytotoxic platinum-doublet chemotherapy that includes antimitotic agents is a current standard of care in advanced non-small cell lung cancer (NSCLC). Microtubule-targeting antimitotics, taxanes, and Vinca alkaloids are effective anticancer therapeutics that affect both dividing and nondividing cells. A new generation of antimitotic agents that target regulatory proteins-mitotic kinases and kinesins-has the potential to overcome the limitations related to the role of tubulin in nondividing cells that are associated with traditional antimitotics. This review concentrates on Polo-like kinase 1, a key regulator of mitosis, outlines a rationale for its development as an anticancer target, and discusses data from preclinical and clinical studies of Plk1 inhibitors with a particular focus on NSCLC. Clin Cancer Res; 17(20); 6459-66. (C) 2011 AACR.

引用

页码：6459 / 6466

页数：8

共 50 条

[31] Regioselective synthesis of benzimidazole thiophene inhibitors of polo-like kinase 1
Hornberger, Keith R.
Badiang, Jennifer G.
Salovich, James M.
Kuntz, Kevin W.
Emmitte, Kyle A.
Cheung, Mui
TETRAHEDRON LETTERS, 2008, 49 (44) : 6348 - 6351
[32] QSAR models for predicting the bioactivity of Polo-like Kinase 1 inhibitors
Kong, Yue
Yan, Aixia
CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2017, 167 : 214 - 225
[33] SYNTHESIS OF SMALL PEPTIDE INHIBITORS TO THE POLO-BOX DOMAIN OF POLO-LIKE KINASE 1
Ahn, M.
Park, J. -E.
Lee, K. S.
Shin, S. Y.
Bang, J. K.
JOURNAL OF PEPTIDE SCIENCE, 2014, 20 : S155 - S155
[34] Structural Optimization and Anticancer Activity of Polo-like Kinase 1 (Plk1) Polo-Box Domain (PBD) Inhibitors and Their Prodrugs
Park, Jung-Eun
Lee, Hobin
Oliva, Paola
Kirsch, Klara
Kim, Bora
Ahn, Jong Il
Alverez, Celeste N.
Gaikwad, Snehal
Krausz, Kristopher W.
O'Connor, Robert
Rai, Ganesha
Simeonov, Anton
Mock, Beverly A.
Gonzalez, Frank J.
Lee, Kyung S.
Jacobson, Kenneth A.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2023, 6 (03) : 422 - 446
[35] Polo-like kinase 1: a potential therapeutic target in human melanoma
Jalili, A.
Moser, A.
Pashenkov, M.
Wagner, C.
Stingl, G.
Ramaswamy, S.
Brunet, J. P.
Golub, T. R.
Wagner, S. N.
EXPERIMENTAL DERMATOLOGY, 2010, 19 (02) : 205 - 205
[36] Polo-Like Kinase 1 Is a Potential Therapeutic Target in Human Melanoma
Jalili, Ahmad
Moser, Anna
Pashenkov, Mikhail
Wagner, Christine
Pathria, Gaurav
Borgdorff, Viola
Gschaider, Melanie
Stingl, Georg
Ramaswamy, Sridhar
Wagner, Stephan N.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (09) : 1886 - 1895
[37] The balance of Polo-like kinase 1 in tumorigenesis
Lin-Yu Lu
Xiaochun Yu
Cell Division, 4
[38] The CINs of Polo-Like Kinase 1 in Cancer
Cunningham, Chelsea E.
MacAuley, Mackenzie J.
Vizeacoumar, Frederick S.
Abuhussein, Omar
Freywald, Andrew
Vizeacoumar, Franco J.
CANCERS, 2020, 12 (10) : 1 - 26
[39] Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers
Stratmann, Jan A.
Sebastian, Martin
LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 67 - 80
[40] The balance of Polo-like kinase 1 in tumorigenesis
Lu, Lin-Yu
Yu, Xiaochun
CELL DIVISION, 2009, 4

← 1 2 3 4 5 →